Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)
Clinical trial NCT06621095 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06621095
- Sponsor
- RenJi Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-30
- Primary completion
- 2025-12-31
- Enrollment
- 104
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.